Reference entry — explicitly NOT a sellable lane. Semaglutide is a patented, FDA-approved blockbuster prescription drug; it cannot be sold here as a cosmetic or "research" peptide, and compounded copies are now largely prohibited (below). It sits in the register for reference and completeness — the
Semaglutide is a GLP-1 receptor agonist and one of the most-prescribed medicines in the world — FDA-approved for type-2 diabetes (Ozempic), obesity (Wegovy) and oral T2D (Rybelsus), with expanded cardiovascular and kidney indications. Its efficacy rests on one of the largest Phase 3 programmes in modern medicine (grade A). The compounded version that flooded the market is now largely prohibited following the February-2025 shortage resolution.
approved (EMA) as Ozempic / Wegovy / Rybelsus.
FDA-approved across multiple indications (Novo Nordisk brands only). Compounding: the injection shortage was declared resolved on 21 Feb 2025; the 503A/503B compounder phase-out deadlines have passed, so compounded semaglutide is now largely prohibited (narrow patient-specific exceptions aside). Gray-market and counterfeit "semaglutide" is unapproved and a documented safety risk.
widely approved.
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026.
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.